NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca’s Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants receiving Tagrisso treatment alone and the other half receiving Tagrisso treatment and chemotherapy; the study will determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints.
There will be an interim analysis following the treatment of 19 patients in each cohort. The company plans to enroll an estimated 74 patients in the phase 2b randomized portion of the study; those patients will be randomized to receive either REQORSA and Tagrisso combination therapy or platinum-based chemotherapy with the primary endpoint of the phase 2b study being progression-free survival. Genprex plans to complete enrollment of phase 2a expansion study by the end of 2024.“Advancing Acclaim-1 marks an important milestone for Genprex,” said Genprex president, chairman and CEO Rodney Varner in the press release. “We are proud of the progress we have made thus far and are encouraged by REQORSA’s potential to improve outcomes for patients battling NSCLC. We look forward to an interim analysis from the phase 2a study in 2025 and expect those results will further validate our novel gene therapy approach to treating lung cancer patients.”
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca’s Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants receiving Tagrisso treatment alone and the other half receiving Tagrisso treatment and chemotherapy; the study will determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints.
There will be an interim analysis following the treatment of 19 patients in each cohort. The company plans to enroll an estimated 74 patients in the phase 2b randomized portion of the study; those patients will be randomized to receive either REQORSA and Tagrisso combination therapy or platinum-based chemotherapy with the primary endpoint of the phase 2b study being progression-free survival. Genprex plans to complete enrollment of phase 2a expansion study by the end of 2024.“Advancing Acclaim-1 marks an important milestone for Genprex,” said Genprex president, chairman and CEO Rodney Varner in the press release. “We are proud of the progress we have made thus far and are encouraged by REQORSA’s potential to improve outcomes for patients battling NSCLC. We look forward to an interim analysis from the phase 2a study in 2025 and expect those results will further validate our novel gene therapy approach to treating lung cancer patients.”
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
